Humacyte Publishes Long-Term Data on Symvess with 92.9% Infection-Free Rate
Humacyte announced the publication of new, long-term data assessing the durability of Symvess in extremity arterial trauma patients in the Journal of Vascular Surgery Cases, Innovations and Techniques, JVS-CIT. The study, titled "Long-term Safety and Efficacy Outcomes of the Acellular Tissue Engineered Vessel, ATEV, in Extremity Arterial Trauma Repair" found that Symvess maintained structural integrity over the long term, exhibited low infection rates, and supported high rates of limb salvage in patients followed for up to 36 months. Among the patients treated in the V005 Phase 2/3 study were 54 patients who underwent extremity vascular repair with Symvess for whom treatment with autologous vein, the standard of care, was not feasible. Within this patient population, once early complications from the traumatic injuries resolved, the rates of conduit infection, limb salvage, and patient survival plateaued and remained relatively constant through the three years of follow-up. Symvess maintained an infection-free rate of 92.9% from months 3-36, with no infections after day 37 and only three conduit infections overall. Limb salvage rates were 87.3% at 12 months and 82.5% at 24 months, despite a severely injured trauma cohort.
Trade with 70% Backtested Accuracy
Analyst Views on HUMA
About HUMA
About the author
BTIG Affirms Buy Rating on Humacyte, Keeps $6 Price Target Intact
Real-time Intelligence: Benzinga Pro offers the fastest news alerts to help traders stay informed and make timely decisions in the stock market.
Exclusive Content: Subscribers gain access to unique stories and insights generated by Benzinga reporters, enhancing their trading strategies.
Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, sharing knowledge and experiences.
Market Winning Tools: The platform is designed to provide traders with the tools and information necessary to succeed in their market endeavors.
D. Boral Capital Reiterates Buy Rating on Humacyte with $25 Price Target Intact
Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders to stay updated on market movements.
Exclusive Content: Subscribers gain access to unique stories and insights generated by Benzinga reporters.
Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, enhancing their trading strategies.
Market Winning Tools: The platform provides essential tools and information to help traders succeed in the stock market.
Benchmark Reaffirms Buy Rating on Humacyte, Adjusts Price Target to $11
Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders to stay updated on market movements.
Exclusive Content: The platform provides exclusive stories and insights generated by Benzinga reporters for its users.
Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, benefiting from shared intelligence.
Market Winning Tools: Benzinga Pro is designed to help traders win in the markets every day with accurate stock market intelligence.
D. Boral Capital Reiterates Buy Rating on Humacyte with $25 Price Target Intact
Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders to stay updated on market movements.
Exclusive Content: The platform provides exclusive stories and insights generated by Benzinga reporters for its users.
Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, enhancing their trading strategies.
Market Winning Tools: Benzinga Pro is designed to help traders win in the markets every day with accurate stock market intelligence.
Robust Earnings and Biotech Strength Drive Midweek Momentum
Kraig Labs' Breakthrough: Kraig Biocraft Laboratories is set to revolutionize the biotechnology sector with its scalable production of recombinant spider silk, utilizing genetically modified silkworms to create high-performance fibers like Dragon Silk™ and Monster Silk®.
Salarius Pharmaceuticals' Offering: Salarius Pharmaceuticals has priced a $7 million public offering to support its merger with Decoy Therapeutics, aiming to enhance R&D and working capital as it prepares for growth.
Humacyte's Q3 Progress: Humacyte reported significant growth in Q3, with revenues increasing to $753,000 and advancements in its bioengineered tissue platform, despite a net loss of $17.5 million.
CorMedix's Record Quarter: CorMedix achieved a remarkable Q3 with net revenues of $104.3 million and a net income of $108.6 million, prompting an increase in its full-year revenue guidance and highlighting its successful turnaround in the biotech sector.
Humacyte Reveals 12-Month Cash Reserves and Boosts Symvess Adoption After Securing $56.5M in Funding
Management Highlights: Humacyte reported significant progress in the commercial launch of Symvess, with product sales increasing to $703,000 and 92 hospitals now eligible to purchase the product. The company also achieved its first sale to U.S. military facilities and received positive clinical outcomes supporting Symvess.
Financial Performance: For Q3 2025, Humacyte generated $0.8 million in revenue, primarily from Symvess sales, and reported a net loss of $17.5 million, an improvement from the previous year. The company has implemented cost-saving measures, reducing research and development expenses significantly.
Pipeline and Future Outlook: Management plans to submit a supplemental BLA for the ATEV program in dialysis access in 2026 and has filed an IND for the CTEV program. They expect interim results from the V012 Phase III trial by April 2026, with a strong cash position to support ongoing operations.
Analyst Sentiment: Analysts expressed a positive outlook on Humacyte's adoption metrics and pricing strategies, with management maintaining confidence in the product's validation through research and expanding market presence, despite ongoing price sensitivity in the hospital market.
BTIG Affirms Buy Rating on Humacyte, Keeps $6 Price Target Intact
Real-time Intelligence: Benzinga Pro offers the fastest news alerts to help traders stay informed and make timely decisions in the stock market.
Exclusive Content: Subscribers gain access to unique stories and insights generated by Benzinga reporters, enhancing their trading strategies.
Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, sharing knowledge and experiences.
Market Winning Tools: The platform is designed to provide traders with the tools and information necessary to succeed in their market endeavors.
D. Boral Capital Reiterates Buy Rating on Humacyte with $25 Price Target Intact
Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders to stay updated on market movements.
Exclusive Content: Subscribers gain access to unique stories and insights generated by Benzinga reporters.
Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, enhancing their trading strategies.
Market Winning Tools: The platform provides essential tools and information to help traders succeed in the stock market.
Benchmark Reaffirms Buy Rating on Humacyte, Adjusts Price Target to $11
Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders to stay updated on market movements.
Exclusive Content: The platform provides exclusive stories and insights generated by Benzinga reporters for its users.
Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, benefiting from shared intelligence.
Market Winning Tools: Benzinga Pro is designed to help traders win in the markets every day with accurate stock market intelligence.
D. Boral Capital Reiterates Buy Rating on Humacyte with $25 Price Target Intact
Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders to stay updated on market movements.
Exclusive Content: The platform provides exclusive stories and insights generated by Benzinga reporters for its users.
Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, enhancing their trading strategies.
Market Winning Tools: Benzinga Pro is designed to help traders win in the markets every day with accurate stock market intelligence.
Robust Earnings and Biotech Strength Drive Midweek Momentum
Kraig Labs' Breakthrough: Kraig Biocraft Laboratories is set to revolutionize the biotechnology sector with its scalable production of recombinant spider silk, utilizing genetically modified silkworms to create high-performance fibers like Dragon Silk™ and Monster Silk®.
Salarius Pharmaceuticals' Offering: Salarius Pharmaceuticals has priced a $7 million public offering to support its merger with Decoy Therapeutics, aiming to enhance R&D and working capital as it prepares for growth.
Humacyte's Q3 Progress: Humacyte reported significant growth in Q3, with revenues increasing to $753,000 and advancements in its bioengineered tissue platform, despite a net loss of $17.5 million.
CorMedix's Record Quarter: CorMedix achieved a remarkable Q3 with net revenues of $104.3 million and a net income of $108.6 million, prompting an increase in its full-year revenue guidance and highlighting its successful turnaround in the biotech sector.
Humacyte Reveals 12-Month Cash Reserves and Boosts Symvess Adoption After Securing $56.5M in Funding
Management Highlights: Humacyte reported significant progress in the commercial launch of Symvess, with product sales increasing to $703,000 and 92 hospitals now eligible to purchase the product. The company also achieved its first sale to U.S. military facilities and received positive clinical outcomes supporting Symvess.
Financial Performance: For Q3 2025, Humacyte generated $0.8 million in revenue, primarily from Symvess sales, and reported a net loss of $17.5 million, an improvement from the previous year. The company has implemented cost-saving measures, reducing research and development expenses significantly.
Pipeline and Future Outlook: Management plans to submit a supplemental BLA for the ATEV program in dialysis access in 2026 and has filed an IND for the CTEV program. They expect interim results from the V012 Phase III trial by April 2026, with a strong cash position to support ongoing operations.
Analyst Sentiment: Analysts expressed a positive outlook on Humacyte's adoption metrics and pricing strategies, with management maintaining confidence in the product's validation through research and expanding market presence, despite ongoing price sensitivity in the hospital market.
